INTRODUCTION {#s1}
============

Nasopharyngeal carcinoma (NPC) is a distinct malignancy of the head and neck with a high incidence (4%-6%) of distant metastases \[[@R1]-[@R3]\]. Metastatic NPC is incurable and devastating, with a median survival of ten to fifteen months using palliative systemic chemotherapy\[[@R4]\]. The current American Joint Committee on Cancer (AJCC/UICC) Tumor, Node, and Metastasis (TNM) staging uses "M1" to denote the TNM stage for all patients with distant metastasis. Therefore, TNM staging ignores the heterogeneity between patients, and this system may exhibit reduced critical accuracy in patients with distant metastases \[[@R1], [@R5], [@R6]\]. NPC patients exhibit common clinical characteristics, such as tumor volume and number, and numerous molecular and hematological markers are also useful to predict outcomes of NPC patients, especially the microcosmic aspect of patients. Compared with molecular markers, hematological markers are more easily applicable to clinical practice because of its convenience and availability.

Palliative chemotherapy benefits the survival of newly diagnosed NPC patients with synchronous distant metastases (mNPC). Previous studies reported improved overall survival (OS) with loco-regional radiotherapy combined with chemotherapy in mNPC patients compared with chemotherapy alone \[[@R7]\]. However, the TNM classification system does not identify which patients should undergo palliative chemotherapy alone or combination treatment. Consequently, it is difficult for clinicians to choose the most suitable treatment for mNPC patients.

The above-mentioned facts prompted us to develop a novel prognostic model based on the clinical characteristics and hematological markers for mNPC patients to correctly predict the survival of mNPC patients and aid clinicians in treatment planning.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The baseline of patients\' clinical features of the primary cohort and validation cohort were displayed in Table [1](#T1){ref-type="table"}. In the primary cohort, patients ranged from 13 to 78 years old (median age, 48 years), and 80% were male. Bone was the most common site of metastasis (66.0%), followed by liver (38.0%) and lung (20.0%). Most patients exhibited multiple sites of metastases at the time of diagnosis (81.0%). The median survival was 22.6 months (range, 3.2--164.3 months). A total of 269 (78.0%) of the 347 patients had died by the last follow-up. The OS rates at 1, 2, 3 and 5 years were 76%, 46%, 31%, and 22%, respectively (data not shown).

###### Clinical characteristics

  Parameters                                            Primary cohort   Validation cohort
  ----------------------------------------------------- ---------------- -------------------
  Sex                                                                    
   Female                                               69               23
   Male                                                 278              83
  Age                                                                    
  \< 48 years                                           173              55
  ≥ 48 years                                            174              51
  T Classification[\*](#tfn_001){ref-type="table-fn"}                    
   T1-2                                                 142              22
   T3-4                                                 205              84
  N Classification[\*](#tfn_001){ref-type="table-fn"}                    
   N0-1                                                 134              25
   N2-3                                                 213              81
  No. of metastatic organs                                               
   Single                                               242              81
   Multiple                                             105              25
  No. of metastatic lesions                                              
   Single                                               65               34
   Multiple                                             282              72
  Oligometastases                                                        
   No                                                   132              44
   Yes                                                  215              62
  Bony metastasis                                                        
   Absent                                               118              32
   Present                                              229              74
  Liver metastasis                                                       
   Absent                                               216              73
   Present                                              131              33
  Lung metastasis                                                        
   Absent                                               278              82
   Present                                              69               24
  Extraregional lymph node metastasis                                    
   Absent                                               299              100
   Present                                              48               6
  Anticancer treatment                                                   
  Systemic chemotherapy alone                           161              40
  Chemotherapy plus radiotherapy                        174              65
  Radiotherapy alone                                    12               1

According to Union for International Cancer Control /American Joint Committee on Cancer (UICC/AJCC) TNM classification system (6th edition, 2002).

Combinational prognostic model via RFE-SVM analysis {#s2_2}
---------------------------------------------------

Experiments of the entire dataset using RFE-SVM analysis identified ten informative variables, including three clinical indexes (oligometastases, N stage, and extraregional lymph node metastasis) and seven hematological markers (EB-VCA IgA, neutrophil count, monocyte count, platelet count, hemoglobin, glutamic-pyruvic transaminase, and glutamyltranspetidase). The ROC curves for each of the ten selected variables and their combination, the mNPC-SVM classifier, illustrated the maximum area under the curve (AUC) for each factor. The AUC for the mNPC-SVM classifier was significantly greater than the AUCs for all other individual prognostic factors (0.761, Figure [1](#F1){ref-type="fig"}). The specificity and sensitivity of mNPC-SVM were 71.3% and 80.7%, respectively. Significant association was observed between the mNPC-SVM and N stage, metastatic organ/lesion involvement and oligometastases by Spearman correlation analysis (Table [2](#T2){ref-type="table"}). In the validation cohort, the AUC for the mNPC-SVM classifier was 0.633 ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}).

###### Association of mNPC -SVM classifier with clinicopathologic characteristics

  Parameters                                            mNPC -SVM classifier   r value   *p* value   
  ----------------------------------------------------- ---------------------- --------- ----------- ---------
  Sex                                                                                                
   Female                                               38                     31        −0.026      0.627
   Male                                                 144                    134                   
  Age                                                                                                
  \< 48 years                                           95                     78        0.049       0.361
   ≥ 48 years                                           87                     87                    
  T Classification[\*](#tfn_002){ref-type="table-fn"}                                                
   T1-2                                                 76                     66        0.018       0.740
   T3-4                                                 106                    99                    
  N Classification[\*](#tfn_002){ref-type="table-fn"}                                                
   N0-1                                                 88                     46        0.21        \<0.001
   N2-3                                                 94                     119                   
  No. of metastatic organs                                                                           
   Single                                               142                    100       0.189       \<0.001
   Multiple                                             40                     65                    
  No. of metastatic lesions                                                                          
   Single                                               49                     16        0.220       \<0.001
   Multiple                                             133                    149                   
  Oligometastases                                                                                    
   No                                                   56                     76        −0.157      0.003
   Yes                                                  126                    89                    
  Bony metastasis                                                                                    
   Absent                                               67                     51        0.062       0.248
   Present                                              115                    114                   
  Liver metastasis                                                                                   
   Absent                                               122                    94        0.104       0.054
   Present                                              60                     71                    
  Lung metastasis                                                                                    
   Absent                                               147                    131       0.017       0.749
   Present                                              35                     34                    
  Extraregional lymph node metastasis                                                                
   Absent                                               161                    138       0.070       0.195
   Present                                              21                     27                    

According to Union for International Cancer Control /American Joint Committee on Cancer (UICC/AJCC) TNM classification system (6th edition, 2002).

![Receiver operating characteristic (ROC) curves for each of the selected ten variables and their combination, the mNPC-SVM classifier, as predictors of death as a result of mNPC within 2 years](oncotarget-07-3645-g001){#F1}

Subdivision of the M1 stage using the mNPC-SVM classifier and overall survival {#s2_3}
------------------------------------------------------------------------------

The mNPC-SVM classifier identified 182 patients as low risk (called the M1a stage) and 165 patients as high risk (defined as the M1b stage). The 2-year overall survival rates differed significantly between M1a and M1b patients (71.4% v 18.8%, *P* \< 0.001). The corresponding overall survival also differed significantly. The median survival time for the low-risk patient group was 38.0 months, and survival time for the high-risk patient group was dramatically reduced to 13.8 months (*P* \< 0.001, Figure [2](#F2){ref-type="fig"}). A similar trend was also observed in the validation cohort (*P* = 0.001, [Supplemental Figure 2](#SD1){ref-type="supplementary-material"}).

![Kaplan--Meier survival analysis of the mNPC-SVM classifier in nasopharyngeal carcinoma patients with synchronous metastases (mNPC)](oncotarget-07-3645-g002){#F2}

Selection of independent prognostic factors of survival {#s2_4}
-------------------------------------------------------

Univariate analysis of the 347 mNPC patients using the mNPC-SVM classifier revealed an apparent association of 5 clinical indexes with OS (Table [3](#T3){ref-type="table"}). The mNPC-SVM classifier remained a powerful predictor of OS after multivariate adjustment using clinicopathological characteristics (predicted low risk vs. predicted high risk, hazard ratio, 3.45; 95% CI, 2.59 to 4.60; *P* \< 0.001). By contrast, there was no significant difference in OS after multivariate adjustment by N stage, metastatic organ/lesion involvement, liver metastasis or extraregional lymph node metastasis (Table [4](#T4){ref-type="table"}).

###### Univariate analysis of clinicopathological and hematological characteristics

  Variables                                             Patients (N =347)   2-Year OS (95% CI)   Unadjusted HR (95%CI)   P
  ----------------------------------------------------- ------------------- -------------------- ----------------------- ---------
  mNPC -SVM classifier                                                                                                   
  Predicted low risk                                    182.00              0.71 (0.51-0.91)     Reference               
  Predicted high risk                                   165.00              0.19 (0.17, 0.21)    3.71 (2.88, 4.79)       \<0.001
  Sex                                                                                                                    
  Male                                                  278.00              0.46 (0.40, 0.52)    Reference               
  Female                                                69.00               0.48 (0.34, 0.62)    0.84 (0.62, 1.14)       0.269
  Age                                                                                                                    
  \< 48 years                                           173.00              0.48 (0.39, 0.57)    Reference               
  ≥ 48 years                                            174.00              0.45 (0.37, 0.53)    1.07 (0.84, 1.36)       0.592
  T Classification[\*](#tfn_003){ref-type="table-fn"}                                                                    
  T1-2                                                  142.00              0.46 (0.37, 0.55)    Reference               
  T3-4                                                  205.00              0.46 (0.39, 0.53)    0.94 (0.74, 1.20)       0.626
  N Classification[\*](#tfn_003){ref-type="table-fn"}                                                                    
  N0-1                                                  134.00              0.57 (0.44, 0.70)    Reference               
  N2-3                                                  213.00              0.39 (0.33, 0.45)    1.38 (1.21, 1.57)       \<0.001
  No. of metastatic organs                                                                                               
  Single                                                242.00              0.53 (0.44, 0.62)    Reference               
  Multiple                                              105.00              0.30 (0.25, 0.35)    1.72 (1.33, 2.21)       \<0.001
  No. of metastatic lesions                                                                                              
  Single                                                65.00               0.60 (0.38, 0.82)    Reference               
  Multiple                                              282.00              0.43 (0.37, 0.49)    1.82 (1.31, 2.55)       \<0.001
  Oligometastases                                                                                                        
  No                                                    132.00              0.48 (0.38, 0.58)    Reference               
  Yes                                                   215.00              0.46 (0.39, 0.53)    0.92 (0.72, 1.18)       0.530
  Bony metastasis                                                                                                        
  Absent                                                118.00              0.45 (0.35, 0.55)    Reference               
  Present                                               229.00              0.47 (0.40, 0.54)    0.89 (0.69, 1.14)       0.359
  Liver metastasis                                                                                                       
  Absent                                                216.00              0.53 (0.44, 0.62)    Reference               
  Present                                               131.00              0.35 (0.39, 0.41)    1.56 (1.22, 1.99)       \<0.001
  Lung metastasis                                                                                                        
  Absent                                                278.00              0.46 (0.40, 0.52)    Reference               
  Present                                               69.00               0.46 (0.31, 0.61)    1.11 (0.82, 1.47)       0.530
  Extraregional lymph node metastasis                                                                                    
  Absent                                                299.00              0.48 (0.41, 0.55)    Reference               
  Present                                               48.00               0.36 (0.25, 0.47)    1.21 (1.03, 1.43)       0.022
  EB-VCAIgA                                                                                                              
  ≤1:160                                                116.00              0.39 (0.32, 0.46)    Reference               
  \>1:160                                               231.00              0.50 (0.42, 0.58)    0.97 (0.75, 1.25)       0.790
  EB-EAIgA                                                                                                               
  ≤1:10                                                 106.00              0.42 (0.33, 0.51)    Reference               
  \>1:10                                                241.00              0.49 (0.42, 0.56)    0.90 (0.70, 1.17)       0.904
  White cell count (per 109 cells/l)                                                                                     
  ≤7.75                                                 197.00              0.53 (0.43, 0.63)    Reference               
  \>7.75                                                150.00              0.38 (0.32, 0.44)    1.39 (1.09, 1.76)       0.008
  Percentage of neutrophils                                                                                              
  ≤0.6825                                               208.00              0.54 (0.44, 0.64)    Reference               
  \>0.6825                                              139.00              0.35 (0.29, 0.41)    2.39 (1.87, 3.05)       \<0.001
  Neutrophil count (per 109 cells/l)                                                                                     
  ≤4.685                                                166.00              0.55 (0.43, 0.67)    Reference               
  \>4.685                                               181.00              0.38 (0.32, 0.44)    1.54 (1.21, 1.96)       \<0.001
  Percentage of lymphocytes                                                                                              
  ≤0.2255                                               149.00              0.32 (0.27, 0.37)    Reference               
  \>0.2255                                              198.00              0.57 (0.46, 0.68)    0.45 (0.35, 0.57)       \<0.001
  Lymphocyte count (per 109 cells/l)                                                                                     
  ≤2.005                                                230.00              0.42 (0.36, 0.48)    Reference               
  \>2.005                                               117.00              0.55 (0.42, 0.68)    0.63 (0.49, 0.83)       \<0.001
  Percentage of monocytes                                                                                                
  ≤0.0765                                               173.00              0.58 (0.46, 0.70)    Reference               
  \>0.0765                                              174.00              0.35 (0.30, 0.40)    1.77 (1.39, 2.25)       \<0.001
  Monocyte count (per 109 cells/l)                                                                                       
  ≤0.5964                                               157.00              0.68 (0.50, 0.86)    Reference               
  \>0.5964                                              190.00              0.29 (0.25, 0.34)    2.45 (1.91, 3.15)       \<0.001
  Red blood cell count (per 1012 cells/l)                                                                                
  ≤4.355                                                132.00              0.26 (0.22, 0.30)    Reference               
  \>4.355                                               215.00              0.59 (0.48, 0.70)    0.46 (0.36, 0.59)       \<0.001
  Hemoglobin (g/l)                                                                                                       
  ≤129.6                                                134.00              0.23 (0.20, 0.26)    Reference               
  \>129.6                                               213.00              0.61 (0.49, 0.73)    0.42 (0.33, 0.54)       \<0.001
  Platelet count (per 109 cells/l)                                                                                       
  ≤287                                                  261.00              0.50 (0.42, 0.58)    Reference               
  \>287                                                 86.00               0.36 (0.28, 0.44)    1.58 (1.21, 2.07)       \<0.001
  Albumin (g/l)                                                                                                          
  ≤40.55                                                95.00               0.24 (0.20, 0.28)    Reference               
  \>40.55                                               252.00              0.55 (0.46, 0.64)    0.40 (0.30, 0.51)       \<0.001
  Globulin (g/l)                                                                                                         
  ≤31.95                                                168.00              0.56 (0.44, 0.68)    Reference               
  \>31.95                                               179.00              0.37 (0.31, 0.43)    1.65 (1.29, 2.10)       \<0.001
  Albumin/globulin ratio                                                                                                 
  ≤1.34                                                 160.00              0.34 (0.29, 0.39)    Reference               
  \>1.34                                                187.00              0.57 (0.45, 0.69)    0.50 (0.39, 0.64)       \<0.001
  Total protein (g/l)                                                                                                    
  ≤65.5                                                 28.00               0.25 (0.17, 0.33)    Reference               
  \>65.5                                                319.00              0.48 (0.42, 0.54)    0.49 (0.33, 0.73)       \<0.001
  AST (u/l)                                                                                                              
  ≤32.8                                                 274.00              0.52 (0.44, 0.60)    Reference               
  \>32.8                                                73.00               0.25 (0.20, 0.30)    2.27 (1.71, 3.00)       \<0.001
  ALT (u/l)                                                                                                              
  ≤54.5                                                 313.00              0.49 (0.42, 0.56)    Reference               
  \>54.5                                                34.00               0.24 (0.18, 0.30)    1.69 (1.15, 2.48)       0.008
  AST/ALT                                                                                                                
  ≤1.21                                                 216.00              0.52 (0.43, 0.61)    Reference               
  \>1.21                                                131.00              0.37 (0.30, 0.44)    1.44 (1.12, 1.83)       0.004
  ALP (u/l)                                                                                                              
  ≤86.95                                                177.00              0.63 (0.48, 0.78)    Reference               
  \>86.95                                               170.00              0.29 (0.25, 0.33)    2.42 (1.89, 3.09)       \<0.001
  GGT (u/l)                                                                                                              
  ≤66                                                   274.00              0.54 (0.45, 0.63)    Reference               
  \>66                                                  73.00               0.19 (0.16, 0.22)    2.35 (1.77, 3.11)       \<0.001
  LDH (u/l)                                                                                                              
  ≤186.5                                                125.00              0.70 (0.46, 0.94)    Reference               
  \>186.5                                               222.00              0.33 (0.29, 0.37)    2.76 (2.10, 3.62)       \<0.001
  AFU (u/l)                                                                                                              
  ≤13.95                                                78.00               0.56 (0.48, 0.74)    Reference               
  \>13.95                                               269.00              0.43 (0.37, 0.49)    0.90 (0.68, 1.19)       0.447
  TBIL (μmol/l)                                                                                                          
  ≤11.65                                                197.00              0.36 (0.31, 0.41)    Reference               
  \>11.65                                               150.00              0.60 (0.44, 0.74)    0.56 (0.43, 0.71)       \<0.001
  DBIL (μmol/l)                                                                                                          
  ≤2.885                                                117.00              0.38 (0.31, 0.45)    Reference               
  \>2.885                                               230.00              0.51 (0.43, 0.59)    0.70 (0.55, 0.90)       0.005
  IBIL (μmol/l)                                                                                                          
  ≤7.935                                                195.00              0.34 (0.29, 0.39)    Reference               
  \>7.935                                               152.00              0.62 (0.47, 0.77)    0.56 (0.44, 0.71)       \<0.001
  HDL-C (mmol/l)                                                                                                         
  ≤0.995                                                119.00              0.28 (0.24, 0.32)    Reference               
  \>0.995                                               228.00              0.56 (0.46, 0.66)    0.49 (0.38, 0.63)       \<0.001
  LDL-C (mmol/l)                                                                                                         
  ≤3.2475                                               214.00              0.43 (0.37, 0.49)    Reference               
  \>3.2475                                              133.00              0.51 (0.39, 0.63)    0.72 (0.56, 0.93)       0.011
  ApoA-I (g/l)                                                                                                           
  ≤1.1575                                               159.00              0.31 (0.26, 0.36)    Reference               
  \>1.1575                                              188.00              0.59 (0.47, 0.61)    0.47 (0.37, 0.60)       \<0.001
  Apo B (g/l)                                                                                                            
  ≤1.045                                                220.00              0.44 (0.38, 0.50)    Reference               
  \>1.045                                               127.00              0.51 (0.39, 0.63)    0.90 (0.70, 1.15)       0.401

Abbreviations: AST: aspartate aminotransferase; ALT: glutamic-pyruvic transaminase; ALP: alkaline phosphatase; GGT: glutamyltranspetidase; LDH: lactate dehydrogenase; AFU: alpha-fucosidase; TBIL: total bilirubin; DBIL: direct bilirubin; IBIL: indirect bilirubin; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA-I: Apolipoprotein A-I; Apo B: Apolipoprotein B;

According to Union for International Cancer Control /American Joint Committee on Cancer (UICC/AJCC) TNM classification system (6th edition, 2002).

###### Multivariate of clinicopathological characteristics

  Variables                                             Adjusted HR (95%CI)   *P*
  ----------------------------------------------------- --------------------- ----------
  mNPC -SVM classifier                                                        
  Predicted low risk                                    Reference             
  Predicted high risk                                   3.45 (2.59, 4.60)     \< 0.001
  Sex                                                                         
  Male                                                  Reference             
  Female                                                0.90 (0.65, 1.24)     0.517
  Age                                                                         
  \< 48 years                                           Reference             
  ≥ 48 years                                            1.06 (0.83, 1.36)     0.643
  T Classification[\*](#tfn_004){ref-type="table-fn"}                         
  T1-2                                                  Reference             
  T3-4                                                  0.97 (0.85, 1.11)     0.642
  N Classification[\*](#tfn_004){ref-type="table-fn"}                         
  N0-1                                                  Reference             
  N2-3                                                  1.13 (0.86, 1.48)     0.389
  No. of metastatic organs                                                    
  Single                                                Reference             
  Multiple                                              1.44 (0.82, 2.55)     0.206
  No. of metastatic lesions                                                   
  Single                                                Reference             
  Multiple                                              1.34 (0.85, 2.13)     0.210
  Oligometastases                                                             
  No                                                    Reference             
  Yes                                                   1.06 (0.71, 1.60)     0.765
  Bony metastasis                                                             
  Absent                                                Reference             
  Present                                               0.74 (0.48, 1.15)     0.185
  Liver metastasis                                                            
  Absent                                                Reference             
  Present                                               1.02 (0.66, 1.58)     0.936
  Lung metastasis                                                             
  Absent                                                Reference             
  Present                                               0.67 (0.41, 1.10)     0.116
  Extraregional lymph node metastasis                                         
  Absent                                                Reference             
  Present                                               1.11 (0.88, 1.39)     0.380

According to Union for International Cancer Control /American Joint Committee on Cancer (UICC/AJCC) TNM classification system (6th edition, 2002).

The mNPC-SVM classifier is an outstanding indicator for the treatment choice {#s2_5}
----------------------------------------------------------------------------

The efficacy of different treatment modalities was also investigated. Fifty-nine of the 182 patients identified as low risk were treated using systemic chemotherapy alone (SCT), 118 patients were treated using chemoradiotherapy (CRT), and 5 patients were treated using radiotherapy (RT). The 1-, 2-, 3- and 5-year OS rates in the SCT and CRT groups were 81.0% vs. 97.0%, 49.0% vs. 82.0%, 26.0% vs. 62.0%, and 10.0% vs. 47.0%, respectively (*P* \< 0.001) (Figure [3A](#F3){ref-type="fig"}). A total of 102 of the 165 patients identified as high risk were treated using SCT, 56 patients were treated using CRT, and 7 patients were treated using RT. The 1-, 2-, 3- and 5-year OS rates in the SCT and CRT groups were 57.0% vs. 68.0%, 18.0% vs. 21.0%, 6.0% vs. 15.0%, and 3.0% vs. 12.0%, respectively (*P* = 0.101) (Figure [3B](#F3){ref-type="fig"}). In the validation cohort, CRT was also associated with significantly better survival outcomes than SCT in the M1a subgroup but not in the M1b subgroup ([Supplemental Figure 3](#SD1){ref-type="supplementary-material"}).

![Kaplan--Meier survival analysis of treatment modality in nasopharyngeal carcinoma patients with synchronous metastases (mNPC) regarding the mNPC-SVM classifier\
CRT, chemoradiotherapy; SCT, systemic chemotherapy alone.](oncotarget-07-3645-g003){#F3}

DISCUSSION {#s3}
==========

TNM staging system is an excellent staging system for NPC patients. However, all patients with distant metastasis are staged as M1, which ignores the heterogeneity between patients. M1 staging may not be a good prognostic value for survival outcome or a good indicator of treatment choice for mNPC patients. Various specially designed prognostic models reportedly demonstrate enhanced prognostic value for patients with distant metastasis \[[@R8], [@R9]\]. However, no further aid for clinicians\' choice of the most suitable treatment for these recurrent patients was evident. Therefore, we developed a novel ten-signature mNPC-SVM classifier to categorize patients with mNPC into high- and low-risk groups. The survival curves were distinctly separate between these two groups. The mNPC-SVM classifier was a significant independent prognostic factor for OS. ROC analyses also suggested that the mNPC-SVM exhibited a better prognostic value than the single indexes or markers. Chemotherapy plus radiotherapy was also associated with an enhanced survival benefit for M1 patients with low risk compared with systemic chemotherapy alone. However, a statistically significant difference was not observed in the CRT group compared with the SCT group for high-risk M1 patients with. M1 stage with low risk was defined as M1a, and M1 stage with high risk was considered M1b.

A single index or marker did not comprehensively reflect patient status. Therefore, our model is not a perfect prognostic model. Univariate analysis and traditional statistics are limited because they ignore the role of combinational potentials that may provide a good prediction of patient survival outcomes. Therefore, machine-learning methods were introduced in cancer classification and prediction because of their powerful capabilities in allowing inferences or decisions to be made that could not otherwise be made using conventional statistical methodologies \[[@R10]-[@R12]\]. Support vector machines (SVMs) are one of the most effective and widely used machine-learning techniques in the field of cancer prediction and prognosis \[[@R10], [@R13], [@R14]\]. The SVM algorithm creates a hyperplane that separates the data into two classes with the maximum margin, which is obtained by calculating the distance between the hyperplane and the closest examples or the margin. The application of different kernels to different data sets can dramatically improve the performance of an SVM classifier.

We designed the SVM models for mNPC via integration of three clinical indexes and seven hematological markers, which reflected the tumorigenesis phenotype of each patient macroscopically and microscopically. Therefore, a multi-biomarker-based model would provide more powerful efficacy for the prediction of patient outcome compared with single clinical index or hematological markers. The factors included in the SVM are used routinely in clinical practice, and they are easily available, which makes the model practical and convenient.

Palliative systemic chemotherapy is the major treatment modality for NPC patients with distant metastasis at diagnosis \[[@R15], [@R16]\]. However, the results of chemotherapy as an initial monotherapy in NPC patients with distant metastasis at diagnosis are not satisfactory. By contrast, radiotherapy or surgery for the primary lesions combined with systemic chemotherapy is beneficial for the survival outcome of these patients with distant metastases. Immunotherapy combined with radical nephrectomy resulted in better survival outcomes over time to progression (5 vs. 3 months, hazard ratio 0.60, 95% CI 0.36-0.97) and median duration of survival (11.1-17 vs. 7-8.1 months, *P* ≤ 0.05) \[[@R17], [@R18]\]. Morgan hypothesized that treatment directed against the primary tumor would retard the progression of existing metastases based on animal models and clinical observations \[[@R19]\]. Similarly, recent reports indicated that locoregional radiotherapy alone or combined with systemic chemotherapy was associated with improved survival of mNPC patients \[[@R7], [@R20]\]. However, these aggressive combination treatments may also result in adverse effects, especially treatment-related complications. Therefore, it is critical to identify patients who would benefit most from aggressive treatment modalities. The current study demonstrated that low-risk (M1a) patients exhibited better survival outcomes compared with high-risk (M1b) patients, but they were more suitable for systematic chemotherapy combined with locoregional radiotherapy. However, locoregional radiotherapy combined with chemotherapy failed to exert significant survival benefits in high-risk (M1b) patients compared to systemic chemotherapy alone.

This retrospective design had several potential limitations. First, although we included the majority of common clinical indexes and hematological markers in the current study, there were other relative indexes that were not included in the study. Therefore, the mNPC-SVM classifier may be further improved by the inclusion of some proven prognostic markers. Second, the efficacy of the combination treatment in high-risk mNPC patients cannot be guaranteed because of differences in the use of loco-regional radiotherapy and systemic chemotherapy in different institutions. Therefore, an optimal combination treatment schedule should be suggested for clinicians to provide the greatest survival benefit to mNPC patients.

In conclusion, the mNPC-SVM classifier exhibited better prognostic value the clinical indexes alone or hematological markers for mNPC patient survival, and this model may aid clinicians\' selection of the most suitable treatment option for mNPC patients. However, we acknowledge that more studies are needed to validate this novel prognostic model.

MATERIALS AND METHODS {#s4}
=====================

Patient data collection {#s4_1}
-----------------------

The primary cohort of 347 mNPC patients for support vector machine (SVM) model development was derived from Sun Yat-sen University Cancer Center (SYSUCC) between January 2000 and December 2010. To examine the generalizability of the model, an validation cohort of 106 mNPC patients were included from SYSUCC between January 2011 and December 2012. Patients were excluded from the trial for any of the following criteria: 1) more than 3 months from the diagnosis of metastasis to pathological proof of NPC; 2) Karnofsky Performance Status score \< 70; or 3) missing clinical/laboratory data. All patients were retrospectively classified into T1-4, N0-3, and M1 based on medical records using the Union for International Cancer Control /American Joint Committee on Cancer (UICC/AJCC) TNM classification system (6th edition, 2002). Bone metastasis was diagnosed based on patient history, physical examination, and imaging studies using a bone scan and/or positron-emission tomography/computed tomography and/or magnetic resonance imaging (MRI). The diagnosis of liver metastasis was based on histological evaluation, ultrasound or computed tomography of the abdomen. Lung metastasis was routinely determined using chest X-ray and/or computed tomography (CT). Pathological confirmation using a biopsy was performed when X-ray and/or CT was insufficient to confirm lung metastasis. The Clinical Ethics Review Board at Cancer Center of Sun Yat-sen University approved this study.

Treatment {#s4_2}
---------

Cisplatin-based systemic chemotherapy was first provided to all patients as the basic treatment according to our institutional guideline for palliative treatment of mNPC. Definitive radiotherapy targeting of the primary tumor and its regional lymph nodes (locoregional radiotherapy, lrRT) was administered to some patients for local symptomatic treatment or as part of a multidisciplinary approach using two-dimensional conventional radiotherapy (2D-CRT) or intensity modulated radiotherapy (IMRT) as previously described \[[@R7], [@R21], [@R22]\].

Patient follow-up {#s4_3}
-----------------

Clinical follow-up visits with each patient were scheduled on a semiannual basis. The follow-up division in the information department of SYSUCC ascertained patient\'s vital status, and follow-up information was updated until death from mNPC or the most recent follow-up, whichever occurred first. Causes of deaths were determined through death certificates, which were supplemented with medical records when necessary. The last follow-up dates were December 30, 2013 and June 30, 2015 for the primary and validation cohort respectively.

Laboratory measurements {#s4_4}
-----------------------

Blood biochemistries of all patients were determined using a Hitachi Automatic Analyzer 7600-020 (Hitachi High-Technologies, Tokyo, Japan). Complete blood count (CBC) was determined using a fully automated hematology analyzer Sysmex XE-5000 (Sysmex, Kobe, Japan). The inclusive criterion for the hematological indexes was the easily accessed variables in clinics.

Selection of cut-off scores {#s4_5}
---------------------------

The sensitivity and specificity of hematological markers as a predictor of death from mNPC within 2 years was plotted to generate a receiver operating characteristic (ROC) curve. We used 2-year OS as the outcome because median patient survival in this study was 22.6 months. ROC curves were used to select cut-off scores to dichotomize each predictor based on the score with the maximum area under the ROC curve (i.e., score nearest to a point on curve \[0.0, 1.0\] with maximum sensitivity and specificity).

Statistical analysis {#s4_6}
--------------------

### Univariate and multivariate analyses {#s4_6_1}

Statistical analysis was performed using SPSS software (version 16.0, SPSS Inc., Chicago, IL). OS was defined as the time interval from the first diagnosis of metastatic NPC to death or the most recent follow-up. Univariate and multivariate analyses of variables were performed using Cox proportional hazards regression models. Actuarial OS was plotted against time using the Kaplan--Meier method, and differences between survival curves were compared using the log-rank test. The correlation of mNPC-SVM model with different clinicopathologic characteristics was evaluated by Spearman\'s rank correlation coefficient (r). The chi-square test was used to analyze differences in proportions. Statistical significance was defined as *P* \< 0.05.

### Prognostic analysis of survival status using machine learning modeling {#s4_6_2}

CBC, blood biochemistry tests and clinical characteristics were combined as whole in this study to comprehensively characterize the survival status of mNPC. Classical machine learning techniques were employed to construct prognostic models and evaluate the prognostic capabilities of the combined factors (called *features* herein) on the models. A subset of features was obtained to achieve the best prognostic performance of patient survival patterns. Patients were dichotomized into two subgroups based on their median OS. Therefore, survival pattern analysis for mNPC was transformed to a binary classification problem, and the SVM model was used to construct prognostic classification models. The clinical parameters were further pruned to a compact yet informative subset to investigate informative variables that could distinguish low-risk patients from high-risk patients. This process is known as feature subset selection (FSS) \[[@R23]-[@R25]\], and we used the well-known Recursive Feature Elimination procedure based on SVM (RFE-SVM). The optimal subset with acceptable prognostic capabilities was obtained, and the SVM model was tested using a ten-fold cross-validation scheme. The entire patient set was dichotomized into two subgroups for risk assessment based on test results. The entire patient dataset was randomly divided into ten equal-sized groups in the ten-fold cross-validation model. Nine groups were used for model construction in each experiment, and the last group was used to test the model performance. The experiment was iterated until every group was tested, and the averaged performance was recorded to quantify the prognostic performance of the model.

SUPPLEMENTARY MATERIAL FIGURES {#s5}
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